Loading institutional data...
Loading institutional data...
Held by 385 of 5,944 reporting institutions (96th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| IBRX | $8.6B | — | — | 75.6× | 668% | 99.3% | -310% | 70.2% | 70.5% | -0.0× | 385 |
Peers = companies sharing IBRX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$309M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: 70%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~3477.2% on $2M of debt.
Cash of $88M fully covers short-term debt of $2M.
Mostly short-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
Where each multiple sits in its own 11-yr range · 9th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 11-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.7 |
| R&D | 118548.9 | 5086.1 | 23059.0 | 20980.5 | 103395.4 | 37357.9 | 1289.5 | — |
| SG&A | 90889.4 | 2109.7 | 11788.1 | 14481.4 | 42795.0 | 20839.2 | 1144.7 | — |
| Operating Income | -209338.3 | -7095.9 | -36509.1 | -35361.9 | -146374.2 | -58239.5 | -2334.2 | -226.0 |
| Income Tax | -1070.2 | -4.8 | -305.1 | 1.0 | 14.2 | -6.4 | 0.0 | -0.1 |
| Net Income | -204736.2 | -7165.2 | -36669.6 | -37451.8 | -173875.0 | -93874.6 | -2805.0 | -310.3 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on IBRX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113.3M 100.0% | $14.7M 100.0% | $622K 100.0% | $240K 100.0% | $934K 100.0% | $605K 100.0% | $2.2M 100.0% | $47K 100.0% | $45K 100.0% | $44K 100.0% |
| Cost of Revenue | $753K 0.7% | $0 0.0% | $0 0.0% | $0 0.0% | — | — | — | — | — | — |
| Research & Development | — | $190.1M 1289.5% | $232.4M 37357.9% | $248.1M 103395.4% | $196.0M 20980.5% | $139.5M 23059.0% | $112.0M 5086.1% | $55.7M 118548.9% | $42.0M 93431.1% | $29.2M 66256.8% |
| Selling, General & Admin | — | $168.8M 1144.7% | $129.6M 20839.2% | $102.7M 42795.0% | $135.3M 14481.4% | $71.3M 11788.1% | $46.5M 2109.7% | $42.7M 90889.4% | $57.1M 126935.6% | $95.4M 216797.7% |
| Total Operating Expenses | $369.3M 326.0% | $358.9M 2434.2% | $362.9M 58339.5% | $351.5M 146474.2% | $331.2M 35461.9% | $221.5M 36609.1% | $158.5M 7195.9% | $98.4M 209438.3% | $99.2M 220366.7% | $124.5M 283054.5% |
| Operating Income | -$256.0M -226.0% | -$344.2M -2334.2% | -$362.3M -58239.5% | -$351.3M -146374.2% | -$330.3M -35361.9% | -$220.9M -36509.1% | -$156.3M -7095.9% | -$98.4M -209338.3% | -$99.1M -220266.7% | -$124.5M -282954.5% |
| Interest Expense | $60.9M 53.7% | $114.6M 777.1% | $128.8M 20715.3% | $63.5M 26464.6% | $14.8M 1589.8% | $9.1M 1499.8% | $5.9M 268.8% | — | $618K 1373.3% | $66K 150.0% |
| Interest & Investment Income | — | — | — | — | — | $1.7M 285.1% | $2.8M 125.5% | $2.3M 4929.8% | $4.2M 9388.9% | $5.2M 11745.5% |
| Other Income (Expense), net | -$95.6M -84.4% | -$69.5M -471.1% | -$221.6M -35633.8% | -$66.0M -27495.0% | -$19.6M -2094.1% | -$5.2M -851.7% | -$4.0M -182.2% | $1.7M 3531.9% | $2.2M 4897.8% | $3.1M 7088.6% |
| Pretax Income | -$351.6M -310.4% | -$413.6M -2805.3% | -$583.9M -93873.3% | -$417.3M -173869.2% | -$349.8M -37456.0% | -$226.0M -37360.8% | -$160.3M -7278.1% | -$96.7M -205806.4% | -$96.9M -215368.9% | -$121.4M -275865.9% |
| Income Tax Expense | -$135K -0.1% | $0 0.0% | -$40K -6.4% | $34K 14.2% | $9K 1.0% | -$1.8M -305.1% | -$105K -4.8% | -$503K -1070.2% | -$493K -1095.6% | -$572K -1300.0% |
| Net Income | -$351.5M -310.3% | -$413.6M -2805.0% | -$583.9M -93874.6% | -$417.3M -173875.0% | -$349.8M -37451.8% | -$221.9M -36669.6% | -$157.8M -7165.2% | -$96.2M -204736.2% | -$96.4M -214273.3% | -$120.8M -274565.9% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.38 | $-0.59 | $-1.15 | $-1.04 | $-0.89 | $-0.59 | $-0.43 | — | — | — |
| EPS (Diluted) | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 | $-0.59 | $-0.43 | — | — | — |
| Weighted Avg Shares (Basic) | 919.9M | 697.3M | 508.6M | 399.9M | 389.2M | 377.1M | 366.3M | — | — | — |
| Weighted Avg Shares (Diluted) | 919.9M | 700.4M | 508.6M | 399.9M | 389.2M | 377.1M | 366.3M | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.